近年来，关于氧化应激、自噬和癌细胞之间关系的研究数量急剧增加。然而，氧化应激和自噬相关基因（OARG）在胃癌（GC）中的重要功能尚未得到全面研究。因此，寻找新的OARG相关生物标志物来预测GC的预后和治疗反应将是一个新的有前景的概念。首先，我们基于对 808 个 GC 样本中具有预后意义的 17 个 OARG 的详细分析，评估了各种氧化应激和自噬相关修饰模式的预后和肿瘤微环境 (TME) 特征的变化。我们确定了三种不同的 OARG 改变模式，它们表现出独特的生物学特征和免疫细胞浸润特征。使用主成分分析方法，开发了 OARGscore 来评估某些肿瘤的 OARG 修饰模式。 OARGscore 与免疫细胞之间的负相关具有统计学意义。预计生存率增加、突变发生率更高以及对免疫治疗的更好反应都与患者的高 OARG 分数有关。此外，还使用oncoPredict程序预测了候选化疗药物。低 OARGscore 组预计将从 Ribociclib、Alisertib、Niraparib、Epirubicin、Olaparib 和 Axitinib 中获益更多，而高 OARGscore 组患者预计将从 Afatinib、Oxaliplatin、紫杉醇、5-氟尿嘧啶、Dabrafenib 和拉帕替尼。我们的研究结果提供了一种预测患者预后和对免疫治疗的敏感性的具体方法，以及对GC中氧化应激和自噬的有希望的见解。

Recent years have seen a sharp rise in the amount of research on the connection between oxidative stress, autophagy, and cancer cells. However, the significant functions of oxidative stress and autophagy-related genes (OARGs) in gastric cancer (GC) are yet to be investigated integrally. Therefore, it will be a new and promising concept to search for novel OARG-related biomarkers to predict the prognosis and treatment response of GC. First, we assessed changes in prognosis and tumor microenvironment (TME) characteristics across the various oxidative stress and autophagy-related modification patterns based on a detailed analysis of 17 OARGs with prognostic significance of 808 GC samples. We identified three distinct OARG alteration patterns which displayed unique biological characteristics and immune cell infiltration features. Using principal component analysis methods, the OARGscore was developed to evaluate the OARG modification patterns of certain tumors. The negative connection between OARGscore and immune cells was statistically significant. Increased survival, a higher incidence of mutations, and a better response to immunotherapy were all predicted to be related to patients' high-OARGscore. In addition, the candidate chemotherapeutic drugs were predicted using the oncoPredict program. The low-OARGscore group was predicted to benefit more from Ribociclib, Alisertib, Niraparib, Epirubicin, Olaparib, and Axitinib, while patients in the high-OARGscore group were predicted to benefit more from Afatinib, Oxaliplatin, Paclitaxel, 5-Fluorouracil, Dabrafenib and Lapatinib. Our findings offer a specific method for predicting a patient's prognosis and susceptibility to immunotherapy, as well as a promising insight of oxidative stress and autophagy in GC.